NSIM
AVXL icon

North Star Investment Management’s Anavex Life Sciences AVXL Stock Holding History

North Star Investment Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-765
Closed -$8K – 1133
2022
Q2 		$8K Hold
765
– – ﹤0.01% 862
2022
Q1 		$9K Buy
+765
New +$9.41K ﹤0.01% 882
2021
Q4 		– Sell
-1,000
Closed -$18K – 1176
2021
Q3 		$18K Buy
+1,000
New +$19.9K ﹤0.01% 754

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

North Star Investment Management's AVXL Position: Q3 2022 in Review

North Star Investment Management sold out of Anavex Life Sciences (AVXL) in Q3 2022, closing a stake of 765 shares — an estimated $8K sold.

North Star Investment Management first reported a position in AVXL in Q3 2021 and held it in 3 quarters. The position peaked at $18K in Q3 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q3 2022.

  • North Star Investment Management reported no remaining Anavex Life Sciences position as of Q3 2022 after selling out during the quarter.
  • North Star Investment Management sold 765 Anavex Life Sciences shares in Q3 2022, an estimated $8K.
  • North Star Investment Management first reported a position in Anavex Life Sciences in Q3 2021 and held it in 3 quarters.
  • North Star Investment Management's Anavex Life Sciences position peaked at $18K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2022.

Based on North Star Investment Management's 13F filing for Q3 2022, filed 2 Nov 2022.